Key Questions to be Answered

Emerg Med. 2010;5(1):33-40. 36. Merli G, Ferrufino CP, Lin J, Hussein M, Battleman D. Hospitalbased costs associated with venous thromboembolism prophylaxis regimens. J Thromb Thrombolysis. 2010;29(4):449-458. 37. Kapoor A, Chuang W, Radhakrishnan N, et al. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics. 2010;28(7):521-538. 38. Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost. 2010;104(4):760-770. 39. Wilbur K, Lynd LD, Sadatsafavi M. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients–a pharmacoeconomic analysis. Clin Appl Thromb Hemost. 2010;17(5):454-465. 40. Spangler EL, Dillavou ED, Smith KJ. Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients. J Vasc Surg. 2010;52(6):1537-1545 e1-2. 41. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253-1258. 42. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977; 296(13):716-721. 43. Drummond MF, Richardson WS, O’Brien BJ, Levine M, Heyland D. Users’ guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-based medicine working group. JAMA. 1997;277(19):1552-1557. 44. Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of ‘‘panel-worthy’’ studies. Med Decis Making. 2000;20(4):451-467. 45. The Guidelines Manual Chapter 8: Incorporating Health Economics. www.nice.org.uk/niceMedia/pdf/GuidelinesManualChapter8.pdf. Accessed May 17, 2012. 46. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335(10):701-707. 47. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Lowmolecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A costeffectiveness analysis. Ann Intern Med. 1999;130(10):789-799. 48. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997;157(3):289-294. 49. Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess. 2007;11(38):iii-iv, ix-66. 50. Hull RD, Raskob GE, Hirsh J, Sackett DL. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. JAMA. 1984;252(2):235-239. 51. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecularweight heparin administered at home. The Tasman study group. N Engl J Med. 1996;334(11):682-687. 52. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecularweight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deepvein thrombosis. N Engl J Med. 1996;334(11):677-681. 53. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2):146-153. 54. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecularweight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062-1072. 55. Hull RD, Pineo GF, Brant RF, et al. Self-managed long-term lowmolecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007;120(1):72-82. 56. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352. 57. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN investigators. N Engl J Med. 2010;363(26):2499-2510. 58. Simpson EL, Stevenson MD, Rawdin A, Papaioannou D. Thrombophilia testing in people with venous thromboembolism: systematic review and cost-effectiveness analysis. Health Technol Assess. 2009;13(2):iii, ix-x, 1-91. 59. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. Br Med J. 2011;342:d3036.